Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
A phase 3 trial of 2-doses Group among 9-14 years in cervical cancer and vaginal cancer, run by Shanghai Bovax Biotechnology Co., Ltd., now recruiting.
Overview
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years is a phase 3 interventional study registered as NCT05027776 by Shanghai Bovax Biotechnology Co., Ltd., with 1348 participants planned, started 2021-09-15 and due to reach its primary completion in 2023-11-22. Interventions recorded: 2-doses Group among 9-14 years, 3-doses Group among 9-19 years and 3-doses Group among 20-26 years.
Similar pages
not linked directly; found by shared links- TrialArtesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)
Shares Vaginal cancer and the tag pipeline.
- TrialPhase II Study of Dysplasix™ Intravaginal Suppositories in Patients Patients With High-Risk HPV and Mild Cervical Cytologic Abnormalities
Shares Vaginal cancer and the tag pipeline.
- TrialA Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialPRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.
- TrialA Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Shares Cervical cancer and the tag pipeline.
- TrialStudy of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
Shares Cervical cancer and the tag pipeline.
- TrialA Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (IVOLGA)
Shares Cervical cancer and the tag pipeline.
- TrialAutologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer
Shares Cervical cancer and the tag pipeline.